Clinical Trials Directory

Trials / Completed

CompletedNCT02110576

Procedure For The Reference Range Study For Absolute MA

Status
Completed
Phase
Study type
Observational
Enrollment
161 (actual)
Sponsor
Haemonetics Corporation · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

CLSI guidelines shall be followed to gather data from a minimum of one hundred and twenty normal donors to create reference intervals for various Haemonetics reagents. Venous blood from a minimum of 146 reference subjects shall be tested. Blood from 160 donors will be drawn at the study site to account for aberrant or outlying data excluded for technical or other reasons.

Detailed description

As part of an examination of how LY30 is calculated, the investigators would like to explore the differences between Maximum Amplitude (MA) and LY30 calculated in the traditional small deviation method and by an absolute MA method. The maximum amplitude (MA) for a sample is determined in real-time using one of two MA-identifying algorithms: Small Deviation MA (the default algorithm) or Absolute MA. Both algorithms are available in commercially available software. Both algorithms find an MA for a sample; however, the difference between the two algorithms is the "acceptance criteria" which each use for identifying the MA. As compared to Small Deviation MA, the Absolute MA has a larger and more stringent rules set. A study will be run to establish reference intervals following the guidelines set out in CLSI document C28-A3c. This guideline calls for a reference interval to be constructed from at least 120 donors. To meet the guidance outlined in the CLSI guideline, we will collect a minimum of 146 donors.

Conditions

Timeline

Start date
2014-05-01
Primary completion
2014-09-01
Completion
2015-03-01
First posted
2014-04-10
Last updated
2015-04-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02110576. Inclusion in this directory is not an endorsement.